Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Last Name

Contact Us
If you have any questions or feedback please contact us.

Philip Reigan

TitleAsst Professor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
    Other Positions
    InstitutionUniversity of Colorado Denver - Anschutz Medical Campus

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Steiger SA, Li C, Backos DS, Reigan P, Natale NR. Dimeric isoxazolyl-1,4-dihydropyridines have enhanced binding at the multi-drug resistance transporter. Bioorg Med Chem. 2017 Jun 15; 25(12):3223-3234. PMID: 28434782.
      View in: PubMed
    2. Casalvieri KA, Matheson CJ, Backos DS, Reigan P. Selective Targeting of RSK Isoforms in Cancer. Trends Cancer. 2017 Apr; 3(4):302-312. PMID: 28718440.
      View in: PubMed
    3. Furtek SL, Matheson CJ, Backos DS, Reigan P. Evaluation of quantitative assays for the identification of direct signal transducer and activator of transcription 3 (STAT3) inhibitors. Oncotarget. 2016 Nov 22; 7(47):77998-78008. PMID: 27793003.
      View in: PubMed
    4. Matheson CJ, Backos DS, Reigan P. Targeting WEE1 Kinase in Cancer. Trends Pharmacol Sci. 2016 Oct; 37(10):872-81. PMID: 27427153.
      View in: PubMed
    5. Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. ACS Chem Biol. 2016 07 15; 11(7):2066-7. PMID: 27304454.
      View in: PubMed
    6. Furtek SL, Backos DS, Matheson CJ, Reigan P. Strategies and Approaches of Targeting STAT3 for Cancer Treatment. ACS Chem Biol. 2016 Feb 19; 11(2):308-18. PMID: 26730496.
      View in: PubMed
    7. Matheson CJ, Venkataraman S, Amani V, Harris PS, Backos DS, Donson AM, Wempe MF, Foreman NK, Vibhakar R, Reigan P. A WEE1 Inhibitor Analog of AZD1775 Maintains Synergy with Cisplatin and Demonstrates Reduced Single-Agent Cytotoxicity in Medulloblastoma Cells. ACS Chem Biol. 2016 Apr 15; 11(4):921-30. PMID: 26745241.
      View in: PubMed
    8. Xiong W, Matheson CJ, Xu M, Backos DS, Mills TS, Salian-Mehta S, Kiseljak-Vassiliades K, Reigan P, Wierman ME. Structure-Based Screen Identification of a Mammalian Ste20-like Kinase 4 (MST4) Inhibitor with Therapeutic Potential for Pituitary Tumors. Mol Cancer Ther. 2016 Mar; 15(3):412-20. PMID: 26721946.
      View in: PubMed
    9. Martinez EC, Passariello CL, Li J, Matheson CJ, Dodge-Kafka K, Reigan P, Kapiloff MS. RSK3: A regulator of pathological cardiac remodeling. IUBMB Life. 2015 May; 67(5):331-7. PMID: 25988524; PMCID: PMC4449288.
    10. Weaver MJ, Kearns AK, Stump S, Li C, Gajewski MP, Rider KC, Backos DS, Reigan PR, Beall HD, Natale NR. AIMing towards improved antitumor efficacy. Bioorg Med Chem Lett. 2015 Apr 15; 25(8):1765-1770. PMID: 25782743; PMCID: PMC4599781.
    11. Jackson BC, Reigan P, Miller B, Thompson DC, Vasiliou V. Human ALDH1B1 polymorphisms may affect the metabolism of acetaldehyde and all-trans retinaldehyde--in vitro studies and computational modeling. Pharm Res. 2015 May; 32(5):1648-62. PMID: 25413692; PMCID: PMC4382438.
    12. Galligan JJ, Fritz KS, Backos DS, Shearn CT, Smathers RL, Jiang H, MacLean KN, Reigan PR, Petersen DR. Oxidative stress-mediated aldehyde adduction of GRP78 in a mouse model of alcoholic liver disease: functional independence of ATPase activity and chaperone function. Free Radic Biol Med. 2014 Aug; 73:411-20. PMID: 24924946; PMCID: PMC4395467.
    13. Krueger AB, Drasin DJ, Lea WA, Patrick AN, Patnaik S, Backos DS, Matheson CJ, Hu X, Barnaeva E, Holliday MJ, Blevins MA, Robin TP, Eisenmesser EZ, Ferrer M, Simeonov A, Southall N, Reigan P, Marugan J, Ford HL, Zhao R. Allosteric inhibitors of the Eya2 phosphatase are selective and inhibit Eya2-mediated cell migration. J Biol Chem. 2014 Jun 06; 289(23):16349-61. PMID: 24755226; PMCID: PMC4047403.
    14. Harris PS, Venkataraman S, Alimova I, Birks DK, Balakrishnan I, Cristiano B, Donson AM, Dubuc AM, Taylor MD, Foreman NK, Reigan P, Vibhakar R. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma. Mol Cancer. 2014 Mar 24; 13:72. PMID: 24661910; PMCID: PMC3987923.
    15. Van Linden AA, Baturin D, Ford JB, Fosmire SP, Gardner L, Korch C, Reigan P, Porter CC. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality. Mol Cancer Ther. 2013 Dec; 12(12):2675-84. PMID: 24121103; PMCID: PMC3897395.
    16. Shearn CT, Smathers RL, Backos DS, Reigan P, Orlicky DJ, Petersen DR. Increased carbonylation of the lipid phosphatase PTEN contributes to Akt2 activation in a murine model of early alcohol-induced steatosis. Free Radic Biol Med. 2013 Dec; 65:680-92. PMID: 23872024; PMCID: PMC3859727.
    17. Backos DS, Fritz KS, McArthur DG, Kepa JK, Donson AM, Petersen DR, Foreman NK, Franklin CC, Reigan P. Glycation of glutamate cysteine ligase by 2-deoxy-d-ribose and its potential impact on chemoresistance in glioblastoma. Neurochem Res. 2013 Sep; 38(9):1838-49. PMID: 23743623.
      View in: PubMed
    18. Sun AQ, Luo Y, Backos DS, Xu S, Balasubramaniyan N, Reigan P, Suchy FJ. Identification of functionally relevant lysine residues that modulate human farnesoid X receptor activation. Mol Pharmacol. 2013 May; 83(5):1078-86. PMID: 23462506; PMCID: PMC3920091.
    19. Vasiliou V, Sandoval M, Backos DS, Jackson BC, Chen Y, Reigan P, Lanaspa MA, Johnson RJ, Koppaka V, Thompson DC. ALDH16A1 is a novel non-catalytic enzyme that may be involved in the etiology of gout via protein-protein interactions with HPRT1. Chem Biol Interact. 2013 Feb 25; 202(1-3):22-31. PMID: 23348497; PMCID: PMC3746320.
    20. Jackson BC, Holmes RS, Backos DS, Reigan P, Thompson DC, Vasiliou V. Comparative genomics, molecular evolution and computational modeling of ALDH1B1 and ALDH2. Chem Biol Interact. 2013 Feb 25; 202(1-3):11-21. PMID: 23247008; PMCID: PMC3687035.
    21. Ryan K, Backos DS, Reigan P, Patel M. Post-translational oxidative modification and inactivation of mitochondrial complex I in epileptogenesis. J Neurosci. 2012 Aug 15; 32(33):11250-8. PMID: 22895709; PMCID: PMC3518304.
    22. Sarsour EH, Kalen AL, Xiao Z, Veenstra TD, Chaudhuri L, Venkataraman S, Reigan P, Buettner GR, Goswami PC. Manganese superoxide dismutase regulates a metabolic switch during the mammalian cell cycle. Cancer Res. 2012 Aug 01; 72(15):3807-16. PMID: 22710435; PMCID: PMC3429130.
    23. Smathers RL, Fritz KS, Galligan JJ, Shearn CT, Reigan P, Marks MJ, Petersen DR. Characterization of 4-HNE modified L-FABP reveals alterations in structural and functional dynamics. PLoS One. 2012; 7(6):e38459. PMID: 22701647; PMCID: PMC3368874.
    24. Shearn CT, Reigan P, Petersen DR. Inhibition of hydrogen peroxide signaling by 4-hydroxynonenal due to differential regulation of Akt1 and Akt2 contributes to decreases in cell survival and proliferation in hepatocellular carcinoma cells. Free Radic Biol Med. 2012 Jul 01; 53(1):1-11. PMID: 22580126; PMCID: PMC3377776.
    25. Backos DS, Franklin CC, Reigan P. The role of glutathione in brain tumor drug resistance. Biochem Pharmacol. 2012 Apr 15; 83(8):1005-12. PMID: 22138445.
      View in: PubMed
    26. Ponder J, Yoo BH, Abraham AD, Li Q, Ashley AK, Amerin CL, Zhou Q, Reid BG, Reigan P, Hromas R, Nickoloff JA, LaBarbera DV. Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIa activity through ATP-competitive inhibition. Mar Drugs. 2011; 9(11):2397-408. PMID: 22163192; PMCID: PMC3229241.
    27. Yan C, Dufour M, Siegel D, Reigan P, Gomez J, Shieh B, Moody CJ, Ross D. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems. Biochemistry. 2011 Aug 09; 50(31):6678-88. PMID: 21718050; PMCID: PMC3291479.
    28. Chong BM, Reigan P, Mayle-Combs KD, Orlicky DJ, McManaman JL. Determinants of adipophilin function in milk lipid formation and secretion. Trends Endocrinol Metab. 2011 Jun; 22(6):211-7. PMID: 21592818; PMCID: PMC3118920.
    29. Shearn CT, Fritz KS, Reigan P, Petersen DR. Modification of Akt2 by 4-hydroxynonenal inhibits insulin-dependent Akt signaling in HepG2 cells. Biochemistry. 2011 May 17; 50(19):3984-96. PMID: 21438592.
      View in: PubMed
    30. Fritz KS, Galligan JJ, Smathers RL, Roede JR, Shearn CT, Reigan P, Petersen DR. 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol. 2011 May 16; 24(5):651-62. PMID: 21449565; PMCID: PMC3113719.
    31. Chong BM, Russell TD, Schaack J, Orlicky DJ, Reigan P, Ladinsky M, McManaman JL. The adipophilin C terminus is a self-folding membrane-binding domain that is important for milk lipid secretion. J Biol Chem. 2011 Jul 01; 286(26):23254-65. PMID: 21383012; PMCID: PMC3123092.
    32. Reigan P, Siegel D, Guo W, Ross D. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins. Mol Pharmacol. 2011 May; 79(5):823-32. PMID: 21285336; PMCID: PMC3082934.
    33. Yan C, Shieh B, Reigan P, Zhang Z, Colucci MA, Chilloux A, Newsome JJ, Siegel D, Chan D, Moody CJ, Ross D. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target. Mol Pharmacol. 2009 Jul; 76(1):163-72. PMID: 19364812; PMCID: PMC2701460.
    34. Roede JR, Carbone DL, Doorn JA, Kirichenko OV, Reigan P, Petersen DR. In vitro and in silico characterization of peroxiredoxin 6 modified by 4-hydroxynonenal and 4-oxononenal. Chem Res Toxicol. 2008 Dec; 21(12):2289-99. PMID: 19548352.
      View in: PubMed
    35. Guo W, Reigan P, Siegel D, Ross D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos. 2008 Oct; 36(10):2050-7. PMID: 18635747; PMCID: PMC2574845.
    36. Colucci MA, Reigan P, Siegel D, Chilloux A, Ross D, Moody CJ. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity. J Med Chem. 2007 Nov 15; 50(23):5780-9. PMID: 17944451; PMCID: PMC2536657.
    37. Reigan P, Gbaj A, Stratford IJ, Bryce RA, Freeman S. Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors. Eur J Med Chem. 2008 Jun; 43(6):1248-60. PMID: 17870212.
      View in: PubMed
    38. Lambert C, Li J, Jonscher K, Yang TC, Reigan P, Quintana M, Harvey J, Freed BM. Acrolein inhibits cytokine gene expression by alkylating cysteine and arginine residues in the NF-kappaB1 DNA binding domain. J Biol Chem. 2007 Jul 06; 282(27):19666-75. PMID: 17491020.
      View in: PubMed
    39. Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, Ross D. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry. 2007 May 22; 46(20):5941-50. PMID: 17455910.
      View in: PubMed
    40. Fang L, Battisti RF, Cheng H, Reigan P, Xin Y, Shen J, Ross D, Chan KK, Martin EW, Wang PG, Sun D. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates. J Med Chem. 2006 Oct 19; 49(21):6290-7. PMID: 17034135; PMCID: PMC2596603.
    41. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol. 2006 Oct; 70(4):1194-203. PMID: 16825487.
      View in: PubMed
    42. Dehn DL, Siegel D, Zafar KS, Reigan P, Swann E, Moody CJ, Ross D. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. Mol Cancer Ther. 2006 Jul; 5(7):1702-9. PMID: 16891456.
      View in: PubMed
    43. Gbaj A, Edwards PN, Reigan P, Freeman S, Jaffar M, Douglas KT. Thymidine phosphorylase from Escherichia coli: tight-binding inhibitors as enzyme active-site titrants. J Enzyme Inhib Med Chem. 2006 Feb; 21(1):69-73. PMID: 16570508.
      View in: PubMed
    44. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 2005 Nov 01; 65(21):10006-15. PMID: 16267026.
      View in: PubMed
    45. Reigan P, Edwards PN, Gbaj A, Cole C, Barry ST, Page KM, Ashton SE, Luke RW, Douglas KT, Stratford IJ, Jaffar M, Bryce RA, Freeman S. Aminoimidazolylmethyluracil analogues as potent inhibitors of thymidine phosphorylase and their bioreductive nitroimidazolyl prodrugs. J Med Chem. 2005 Jan 27; 48(2):392-402. PMID: 15658853.
      View in: PubMed
    46. Reigan P, Gbaj A, Chinje E, Stratford IJ, Douglas KT, Freeman S. Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase. Bioorg Med Chem Lett. 2004 Nov 01; 14(21):5247-50. PMID: 15454205.
      View in: PubMed
    47. Cole C, Reigan P, Gbaj A, Edwards PN, Douglas KT, Stratford IJ, Freeman S, Jaffar M. Potential tumor-selective nitroimidazolylmethyluracil prodrug derivatives: inhibitors of the angiogenic enzyme thymidine phosphorylase. J Med Chem. 2003 Jan 16; 46(2):207-9. PMID: 12519058.
      View in: PubMed
    Reigan's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    Co-Authors Expand Description
    Similar People Expand Description
    Same Department Expand Description
    Physical Neighbors Expand Description

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)